




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07D 401/14, A61K 31/44, C07D 487/04, 409/14		A1	(11) International Publication Number: WO 99/07700
			(43) International Publication Date: 18 February 1999 (18.02.99)
(21) International Application Number: PCT/EP98/05116		(81) Designated States: CA, JP, US, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).	
(22) International Filing Date: 6 August 1998 (06.08.98)			
(30) Priority Data: 9716804.1 9 August 1997 (09.08.97) GB 9801633.0 26 January 1998 (26.01.98) GB		Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>	
(71) Applicant (for all designated States except US): SMITHKLINE BEECHAM PLC (GB/GB); New Horizons Court, Brentford, Middlesex TW8 9EP (GB).			
(72) Inventors; and			
(75) Inventors/Applicants (for US only): GASTER, Laramie, Mary [GB/GB]; SmithKline Beecham Pharmaceuticals, New Frontiers Science Park South, Third Avenue, Harlow, Essex CM19 5AW (GB). WYMAN, Paul, Adrian [GB/GB]; SmithKline Beecham Pharmaceuticals, New Frontiers Science Park South, Third Avenue, Harlow, Essex CM19 5AW (GB). FLYNN, Sean, Thomas [GB/GB]; SmithKline Beecham Pharmaceuticals, The Frythe, Welwyn, Herts AL6 9AR (GB).			
(74) Agent: WATERS, David, Martin; SmithKline Beecham plc, 2 New Horizons Court, Brentford, Middlesex TW8 9EP (GB).			
(54) Title: BICYCLIC COMPOUNDS AS LIGANDS FOR 5-HT ₁ RECEPTORS			
 <p style="text-align: center;">(I)</p>			
(57) Abstract			
<p>The invention relates to compounds of formula (I) which are ligands for 5-HT₁, processes for their preparation, to compositions containing them and to their use in the treatment of CNS disorders.</p>			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.


AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

BICYCLIC COMPOUNDS AS LIGANDS FOR 5HT₁ RECEPTORS

The present invention relates to novel compounds, processes for their preparation, and pharmaceutical compositions containing them.


- 5 EPA 0733628 discloses a series of indole derivatives which are said to possess 5HT_{1F} agonist activity. These compounds are alleged to be of use in the treatment of migraine and associated disorders. EPA 0533266/7/8 disclose a series of benzanilide derivatives which are said to possess 5-HT_{1D} receptor antagonist activity. The 5-HT_{1D} receptor was subsequently found to consist of a pair of gene products originally
- 10 designated 5-HT_{1D α} and 5-HT_{1D β} receptors which have more recently been reclassified as 5-HT_{1D} and 5-HT_{1B} receptors, respectively. (Hartig, P.R. et al., Trends in Pharmacological Sciences 1992, Vol. 13, page 152, Hartig, P.R. et al., Trends in Pharmacological Sciences, 1996, Vol. 17, page103).

- A structurally distinct class of compounds have now been found that are ligands
- 15 for 5HT_{1A}, 5HT_{1B} and 5HT_{1D} receptors. It is expected that such compounds will be useful for the treatment and prophylaxis of various disorders. In a first aspect, the present invention therefore provides a compound of formula (I) or a salt thereof:



20

in which R^a is a group of formula (i)




- 25 in which P¹ is phenyl, bicyclic aryl, a 5 to 7 membered heterocyclic ring containing 1 to 3 heteroatoms selected from oxygen, nitrogen and sulphur, or a bicyclic heterocyclic ring containing 1 to 3 heteroatoms selected from oxygen, nitrogen and sulphur;
 R¹ is hydrogen, halogen, C₁₋₆alkyl, C₃₋₆cycloalkyl, COC₁₋₆alkyl, C₁₋₆alkoxy, hydroxy, hydroxyC₁₋₆alkyl, hydroxyC₁₋₆alkoxy, C₁₋₆alkoxyC₁₋₆alkoxy, nitro, trifluoromethyl, cyano, SR⁹, SOR⁹, SO₂R⁹, SO₂NR¹⁰R¹¹, CO₂R¹⁰, CONR¹⁰R¹¹,
 30 CONR¹⁰(CH₂)₆CO₂R¹¹, (CH₂)₆NR¹⁰R¹¹, (CH₂)₆CONR¹⁰R¹¹, (CH₂)₆NR¹⁰COR¹¹, (CH₂)₆CO₂C₁₋₆alkyl, CO₂(CH₂)₆OR¹⁰, NR¹⁰R¹¹, NR¹⁰CO₂R¹¹,

$\text{NR}^{10}\text{CONR}^{10}\text{R}^{11}$, $\text{CR}^{10}=\text{NOR}^{11}$ where R^9 is C_{1-6} alkyl, R^{10} and R^{11} are independently hydrogen or C_{1-6} alkyl and c is 1 to 4;

R^2 is hydrogen, halogen, C_{1-6} alkyl, C_{3-6} cycloalkyl, C_{3-6} cycloalkenyl, C_{1-6} alkoxy, COC_{1-6} alkyl, aryl, acyloxy, hydroxy, nitro, trifluoromethyl, cyano, CO_2R^{10} ,

- 5 $\text{CONR}^{10}\text{R}^{11}$, $\text{NR}^{10}\text{R}^{11}$ where R^{10} and R^{11} are as defined in R^1 ;
 a is 1, 2 or 3;

or R^a is a group of formula (ii)



10

wherein P^2 and P^3 are independently phenyl, bicyclic aryl, a 5- to 7-membered heterocyclic ring containing 1 to 3 heteroatoms selected from oxygen, nitrogen and sulphur, or a bicyclic heterocyclic group containing 1 to 3 heteroatoms selected from oxygen, nitrogen or sulphur;

- 15 A is a bond or oxygen, $\text{S}(\text{O})_m$ where m is 0, 1 or 2, carbonyl, or CH_2 or NR^4 where R^4 is hydrogen or C_{1-6} alkyl;

R^1 is as defined above for formula (i) or is a 5 to 7-membered heterocyclic ring, containing 1 to 3 heteroatoms selected from oxygen, nitrogen or sulphur, optionally substituted by C_{1-6} alkyl, halogen or C_{1-6} alkanoyl;

- 20 R^2 and R^3 are as defined for R^2 in formula (i);
 and a and b are independently 1, 2 or 3;

L is a group of formula

- $\text{Y} - \text{C}(=\text{V}) - \text{DG} -$

- 25 in which Y is - $\text{NH} -$, NR^5 where R^5 is C_{1-6} alkyl, or Y is - $\text{CH}_2 -$ or - $\text{O} -$,
 V is oxygen or sulphur;

D is nitrogen, carbon or a CH group, G is hydrogen or C_{1-6} alkyl, providing that D is nitrogen or a CH group, or G together with R^b forms a group W where W is $(\text{CR}^{16}\text{R}^{17})_t$, where t is 2, 3 or 4 and R^{16} and R^{17} are independently hydrogen or C_{1-6} alkyl or W is

- 30 $(\text{CR}^{16}\text{R}^{17})_u - \text{J}$ where u is 0, 1, 2 or 3 and J is oxygen, sulphur, $\text{CR}^{16}=\text{CR}^{17}$, $\text{CR}^{16}=\text{N}$, $=\text{CR}^{16}\text{O}$, $=\text{CR}^{16}\text{S}$ or $=\text{CR}^{16}-\text{NR}^{17}$ provided that u is not 0 when J is oxygen or sulphur;

subject to the proviso that when D is nitrogen, G is hydrogen or C₁₋₆alkyl, Q is selected such that together with the phenyl ring to which it is attached it forms an indole ring and further that when:

- (a) Y is -NH- or -NR⁵- and V is oxygen or sulphur; or
- 5 (b) both Y and V are oxygen; or
- (c) Y is CH₂ and V is oxygen

then P¹ is not phenyl within the definition of R^a formula (i) and

R^a is not an unsubstituted biphenyl within the definition of formula (ii)

- 10 Q is an optionally substituted 5- to 7- membered carbocyclic or heterocyclic ring containing 1 to 3 heteroatoms selected from oxygen, nitrogen or sulphur;
R^y is a 5- to 7-membered heterocyclic ring containing 1 to 3 heteroatoms selected from oxygen, nitrogen and sulphur;
R^b is hydrogen, halogen, hydroxy, C₁₋₆alkyl, trifluoromethyl, C₁₋₆alkoxy or aryl; or R^b
15 together with G forms a group W as defined above;

- C₁₋₆alkyl groups whether alone or as part of another group may be straight chain or branched. The term 'acyloxy' is used herein to describe a group -OC(O)C₁₋₆alkyl. The term 'aryl' is used herein to describe, unless otherwise stated, a group such as phenyl. The
20 term 'aralkyl' is used herein to describe, unless otherwise stated, a group such as benzyl.

The bicyclic aryl group represented by P¹, P² and/or P³, which may be partially saturated, is preferably naphthyl.

- Examples of bicyclic heterocyclic rings containing 1 to 3 heteroatoms selected from oxygen, nitrogen and sulphur include quinoline, isoquinoline, indole, benzofuran
25 and benzothiophene rings. The heterocyclic groups can be linked to the remainder of the molecule via a carbon atom or, when present, a suitable nitrogen atom.

- Examples of 5 to 7 membered heterocyclic rings containing 1 to 3 heteroatoms selected from oxygen, nitrogen and sulphur represented by P¹, P² and/or P³, include
30 thienyl, furyl, pyrrolyl, triazolyl, imidazolyl, oxazolyl, thiazolyl, oxadiazolyl, isothiazolyl, isoxazolyl, thiadiazolyl, pyrimidyl and pyrazinyl, preferably pyridyl.

R¹ is preferably a halogen atom for example, fluorine, chlorine or bromine, and R² and/or R³ are each preferably hydrogen, halogen for example a chloro group or a C₁₋₆alkyl group for example a methyl group.

a and b are each preferably 1 or 2.

- 35 Within the definition of R^a formula (ii), A is preferably a bond.

In the group L, as defined above:-

Y is preferably -NH-.

V is preferably oxygen.

D is preferably nitrogen and G is preferably a hydrogen atom or together with R^b forms group W, preferably -(CH₂)₂.

- 5 R^b is preferably hydrogen or R^b together with G forms group W referred to above.

Suitably Q is an optionally substituted 5 to 7-membered heterocyclic ring containing 1 to 3 heteroatoms selected from oxygen, nitrogen or sulphur. Preferably Q is a 5- or 6-membered ring containing one or two heteroatoms. Preferably Q, together with the phenyl group to which it is attached, forms an indole, indoline, benzoxazole, benzopyran, benzothiophene or benzoxazine ring. Suitable optional substituents for the ring Q include groups R¹ and R² as defined above, preferably C₁₋₆alkyl, most preferably methyl.

- 15 The group RY can be fully or partially saturated and can be linked to the group Q via a carbon atom or, when present, a suitable nitrogen atom. Preferably RY is 5 or 6 membered heterocyclic containing 1 or 2 nitrogen atoms. Most preferably RY is a piperidinyl group.

Particularly preferred compounds according to the invention include:-

- 20 N-[3-(1-Methylpiperidin-4-yl)indol-5-yl]-N'-[4-(pyridin-4-yl)naphth-1-yl]-urea,
N-[3-(1-Methylpiperidin-4-yl)indol-5-yl]-N'-[3-methyl-4-(pyridin-4-yl)phenyl]-urea,
N-[2,3-Dichloro-4-(pyridin-4-yl)phenyl]-N'-[3-(1-methylpiperidin-4-yl)indol-5-yl]-urea,
N-[2-Chloro-4-(pyridin-4-yl)phenyl]-N'-[3-(1-methylpiperidin-4-yl)indol-5-yl]-urea
N-[3-(1-Methylpiperidin-4-yl)indol-5-yl]-4-(pyridin-4-yl)naphth-1-ylacetamide,
25 N-[2,3-Dichlorophenyl]-N'-[7-(1-methylpiperidin-4-yl)-1,2,3,5-tetrahydropyrrolo[2,3-f]indol-1-yl]-urea,
N-[7-(1-Methylpiperidin-4-yl)-1,2,3,5-tetrahydropyrrolo[2,3-f]indol-1-yl]-N'-[4-(pyridin-4-yl)naphth-1-yl]-urea,
N-[3-Chloro-4-(pyridin-4-yl)phenyl]-N'-[3-(1-methylpiperidin-4-yl)indol-5-yl]-urea,
30 N-[3-Chloro-4-(pyridin-4-yl)phenyl]-N'-[3-(1-methyl-1,2,5,6-tetrahydropyridin-4-yl)benzo[b]thiophen-5-yl]-urea,
N-[3-(1-Methyl-1,2,5,6-tetrahydropyridin-4-yl)benzo[b]thiophen-5-yl]-N'-[4-(pyridin-4-yl)naphth-1-yl]-urea,
N-[3-Chloro-4-(pyridin-4-yl)phenyl]-N'-[3-(1-methylpiperidin-4-yl)benzo[b]thiophen-5-yl]-urea,
35

N-[3-(1-Methylpiperidin-4-yl)benzo[b]thiophen-5-yl]-N'-[4-(pyridin-4-yl)naphth-1-yl]-urea
or pharmaceutically acceptable salts thereof.

- Preferred salts of the compounds of formula (I) are pharmaceutically acceptable salts. These include acid addition salts such as hydrochlorides, hydrobromides, phosphates, acetates, fumarates, maleates, tartrates, citrates, oxalates, methanesulphonates and p-toluenesulphonates.


Certain compounds of formula (I) are capable of existing in stereoisomeric forms. It will be understood that the invention encompasses all geometric and optical isomers of the compounds of formula (I) and the mixtures thereof including racemates.

Compounds of the invention can be prepared using procedures known in the art. In a further aspect the present invention provides a process for the preparation of a compound of formula (I) or a pharmaceutically acceptable salt thereof which comprises:

- (a) where D is nitrogen and Y is NH, coupling a compound of formula (II):




- in which R^a and V are as defined in formula (I) or a protected derivative thereof with a compound of formula (III).




(III)

- in which R^b , R^v , G, and Q are as defined in formula (I), or a protected derivative thereof;
or
(b) where D is nitrogen and Y is NH or NR^5 , reacting a compound of formula (IV)



- in which R^a and R^5 are as defined in formula (I) with a compound of formula (III) together with an appropriate urea forming agent;
(c) where D is nitrogen, reacting a compound of formula (V)




in which R^a is as defined in formula (I),

Y is $-CH_2-$ or $-O-$ and L^2 is an appropriate leaving group, with a compound of formula (III)

(d) where D is carbon or CH, reacting a compound of formula (VI)



in which R^a is as defined in formula (I) with a compound of formula (VII)



(VII)

in which D is carbon or CH, R^b , R^y , G, and Q are as defined in formula (I) and L^2 is an appropriate leaving group and optionally thereafter:

- removing any protecting groups,
- converting a compound of formula (I) into another compound of formula (I),
- forming a pharmaceutically acceptable salt.

The reaction in process (a) is conveniently effected in an organic solvent such as dichloromethane.

In process (b) the urea forming agent can be carbonyl diimidazole, triphosgene or phosgene, and carried out in an inert organic solvent such as dimethylformamide, tetrahydrofuran or dichloromethane at ambient or elevated temperature in the presence of a base such as triethylamine or pyridine.

In process (c) the leaving group L^2 may be a halogen e.g. chloro group and the reaction may be carried out in an inert organic solvent such as tetrahydrofuran or dichloromethane at ambient or elevated temperature in the presence of a base such as triethylamine or pyridine.

In process (d) the leaving group L^2 may be a halogen e.g. chloro group and the reaction may be carried out in an inert organic solvent such as tetrahydrofuran or

dichloromethane at ambient or elevated temperature in the presence of a base such as triethylamine or pyridine.

Compounds of formula (I) can be converted into further compounds of formula (I) using standard techniques.

- 5 Intermediate compounds of formula (II), (III), (IV), (V), (VI) and (VII) can be prepared using standard procedures known in the art.

It will be appreciated to those skilled in the art that it may be necessary to protect certain reactive substituents during some of the above procedures. Standard protection and deprotection techniques can be used. For example, primary amines can be protected as phthalimide, benzyl, benzyloxycarbonyl or trityl derivatives. These groups can be removed by conventional procedures well known in the art.

10 Carboxylic acid groups can be protected as esters. Aldehyde or ketone groups can be protected as acetals, ketals, thioacetals or thioketals. Deprotection is achieved using standard conditions.

15

The involvement of serotonin receptors in a number of pharmacological effects has been reviewed by R. A. Glennon in "Serotonin Receptors: Clinical Implications", Neuroscience and Behavioural Reviews, 1990, 14, 35 and by L.O. Wilkinson and C.T. Dourish in "Serotonin Receptor Subtypes: Basic and Clinical Aspects" S. Peroutka Ed., John Wiley and Sons, New York, 1991 p. 147.

20 Serotonin (5-hydroxytryptamine; 5HT) receptors have been implicated in a number of pharmacological effects including mood disorders including depression, seasonal affective disorder and dysthymia, anxiety disorders, including generalised anxiety, panic disorder, agoraphobia, social phobia, obsessive compulsive disorder and post-traumatic stress disorder; memory disorders, including dementia, amnesic disorders
25 and age-associated memory impairment; disorders of eating behaviours, including anorexia nervosa and bulimia nervosa, sleep disorders (including disturbances of Circadian rhythm), motor disorders such as Parkinson's disease, dementia in Parkinson's disease, neuroleptic-induced Parkinsonism and tardive dyskinesias, as well as other
30 psychiatric disorders. Serotonin receptor ligands have been shown to be of use in the treatment of emesis and nausea and may also be of use in endocrine disorders such as hyperlactinaemia, vasospasm (particularly in the cerebral vasculature), cerebellar ataxia and hypertension, as well as disorders of the gastrointestinal tract where changes in motility and secretion are involved. They may also be of use in the treatment of sexual
35 dysfunction and hypothermia.

Ligands with high affinity for the 5HT₁ receptors are well recognised as having therapeutic utility for the treatment of the the above conditions. For example: WO 95/31988 refers to the use of a 5-HT_{1D} receptor antagonist in conjunction with a 5-HT_{1A} receptor antagonist to treat CNS, endocrine and GI disorders; K. Rasmussen (Annual Reports in Medicinal Chemistry, (1995) 30, 1) describes the utility of 5-HT_{1A} receptor agonists and partial agonists in the treatment of various CNS disorders; P. Trouillas (Progress in Brain Research, C.I. de Zeeuw, P. Stara and J. Voogd, Eds. 1997, 144, 589) and G. Maura (J. Neurochemistry, 1996, 66, 202) propose that administration of agonist ligands selective for the 5-HT_{1A} receptor or for both 5-HT_{1A} and 5-HT_{1D} receptors should provide effective treatment for human cerebellar ataxias.

The present invention also provides a compound of general formula (I) or a physiologically acceptable salt or solvate thereof for use in the treatment of the aforementioned disorders.

In a further aspect the invention provides a method of treating the aforementioned disorders which comprises administering an effective amount to a patient in need of such treatment of a compound of general formula (I) or a pharmaceutically acceptable salt or solvate thereof.

In particular the invention provides a compound of general formula (I) or a physiologically acceptable salt or solvate thereof for use in the treatment or prophylaxis of depression.

The affinities of the compounds of this invention for the 5HT_{1A}, 5-HT_{1B} and 5-HT_{1D} receptors can be determined by the following radioligand binding assay. HEK 293 cells expressing 5-HT_{1A} receptors (4×10^7 /ml) are homogenised in Tris buffer and stored in 1ml aliquots. CHO cells expressing 5-HT_{1B} receptors (4×10^7 cells/ml) are homogenised in Tris buffer and stored in 1.5 ml aliquots. CHO cells expressing 5-HT_{1D} receptors (0.563×10^8 /ml) are homogenised in Tris buffer and stored in 1 ml aliquots. 0.4 ml of a cell suspension is incubated with [³H]-5-HT (4nM) for 5-HT_{1B/1D} receptors and [³H]-8-OH DPAT (1nM) for 5-HT_{1A} receptors in Tris Mg HCl buffer (pH 7.7) and test drug, at 37°C for 45 minutes. Each test drug is tested at 10 concentrations (0.01 mM to 0.3 nM final concentration), with non-specific binding defined using 0.01 mM 5-HT. The total assay volume is 0.5 ml. Incubation is stopped by rapid filtration using a Packard Filtermate (filters pre-soaked in 0.3% polyethylenimine) and radioactivity measured by Topcount scintillation counting. pKi values are calculated from the IC₅₀ generated by an iterative least squares curve fitting programme.

The intrinsic activity of the compounds of this invention can be determined according to the following procedure. HEK293 cell membranes stably expressing human

5-HT_{1A} receptors and CHO cell membranes stably expressing human 5-HT_{1B} receptors are homogenised in HEPES/EDTA buffer and stored in 1ml aliquots, and [³⁵S]GTPγS binding studies are carried out essentially as described by Lazareno *et al.*, (Life Sci., 1993, 52, 449) with some minor modifications. Membranes from 10⁶ cells are pre-
5 incubated at 30°C for 30 minutes in 20 mM HEPES buffer (pH 7.4) in the presence of MgCl₂ (3 mM), NaCl (100 mM), GDP (10 μM) and ascorbate (0.2 mM), with or without test compounds. The reaction is started by the addition of 10 μl of [³⁵S]GTPγS (100 pM, assay concentration) followed by a further 30 minutes incubation at 30°C. Non-specific binding is determined using nonradiolabelled GTPγS (20 μM) added prior to the
10 membranes. The reaction is terminated by rapid filtration through Whatman GF/B grade filters followed by 5 x 1 ml washes with ice cold HEPES (20 mM) /MgCl₂ (3 mM) buffer. Radioactivity is measured using liquid scintillation spectrometry. This procedure is hereafter referred to as the [³⁵S]GTPγS functional assay.

The compounds of formula (I) show high affinity for the 5HT_{1A}, 5-HT_{1B} and
15 5-HT_{1D} receptors. It has been found, using the [³⁵S]GTPγS functional assay, that certain compounds of formula (I) appear to be antagonists whilst others appear to be agonists, partial agonists or inverse agonists. The difficulties in describing intrinsic activity of drugs acting at G protein coupled receptors is recognised in the art (Hoyer and Boddeke, Trends in Pharmacological Sciences, July 1993, [Vol. 14], page 270-275). We
20 believe that however these ligands are classified according to this functional assay, the compounds of this invention will be useful antidepressants *in vivo*.

It will be appreciated by those skilled in the art that the compounds according to the invention may advantageously be used in conjunction with one or more other therapeutic agents, for instance, a selective serotonin reuptake inhibitor (SSRI)
25 antidepressant.

The present invention also provides a pharmaceutical composition, which comprises a compound of formula (I) or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

A pharmaceutical composition of the invention, which may be prepared by
30 admixture, suitably at ambient temperature and atmospheric pressure, is usually adapted for oral, parenteral or rectal administration and, as such, may be in the form of tablets, capsules, oral liquid preparations, powders, granules, lozenges, reconstitutable powders, injectable or infusible solutions or suspensions or suppositories. Orally administrable compositions are generally preferred.

35 Tablets and capsules for oral administration may be in unit dose form, and may contain conventional excipients, such as binding agents, fillers, tableting lubricants,

disintegrants and acceptable wetting agents. The tablets may be coated according to methods well known in normal pharmaceutical practice.

Oral liquid preparations may be in the form of, for example, aqueous or oily suspensions, solutions, emulsions, syrups or elixirs, or may be in the form of a dry product for reconstitution with water or other suitable vehicle before use. Such liquid preparations may contain conventional additives such as suspending agents, emulsifying agents, non-aqueous vehicles (which may include edible oils), preservatives, and, if desired, conventional flavourings or colorants.

For parenteral administration, fluid unit dosage forms are prepared utilising a compound of the invention or pharmaceutically acceptable salt thereof and a sterile vehicle. The compound, depending on the vehicle and concentration used, can be either suspended or dissolved in the vehicle. In preparing solutions, the compound can be dissolved for injection and filter sterilised before filling into a suitable vial or ampoule and sealing. Advantageously, adjuvants such as a local anaesthetic, preservatives and buffering agents are dissolved in the vehicle. To enhance the stability, the composition can be frozen after filling into the vial and the water removed under vacuum. Parenteral suspensions are prepared in substantially the same manner, except that the compound is suspended in the vehicle instead of being dissolved, and sterilisation cannot be accomplished by filtration. The compound can be sterilised by exposure to ethylene oxide before suspension in a sterile vehicle. Advantageously, a surfactant or wetting agent is included in the composition to facilitate uniform distribution of the compound.

The composition may contain from 0.1% to 99% by weight, preferably from 10 to 60% by weight, of the active material, depending on the method of administration.

The dose of the compound used in the treatment of the aforementioned disorders will vary in the usual way with the seriousness of the disorders, the weight of the sufferer, and other similar factors. However, as a general guide suitable unit doses may be 0.05 to 1000 mg, more suitably 1.0 to 200 mg, and such unit doses may be administered more than once a day, for example two or three a day. Such therapy may extend for a number of weeks or months.

The following Examples illustrate the preparation of compounds of the invention.

Description 1

3-(1-Methyl-1,2,5,6-tetrahydropyridin-4-yl)-5-nitro-1H-indole (D1)

A stirred mixture of 5-nitro-1H-indole (1.94g, 12 mmole), 1-methylpiperidin-4-one (2.71g, 24 mmole) and sodium methoxide (3.89g, 72 mmole) in dry methanol (100ml) was heated to reflux for 30h. The cooled mixture was concentrated by evaporation and

neutralized with 2M HCl acid. The resultant yellow precipitate was collected by filtration, washed with water and dried *in vacuo* to afford the title compound as a yellow powder (2.01g).

- ¹H NMR (250MHz, d⁶DMSO) δ (ppm): 11.75 (s, 1H), 8.50 (s, 1H), 7.81 (dd, 1H), 7.52 (d, 1H), 7.38 (d, 1H), 5.91 (s, 1H), 2.72 (m, 4H), 2.41 (s, 3H) (NB - 2H signals obscured by water signal).

Description 2

5-Amino-3-(1-methylpiperidin-4-yl)-1H-indole (D2)

- A mixture of 3-(1-methyl-1,2,5,6-tetrahydropyridin-4-yl)-5-nitro-1H-indole (D1, 2.00g, 7.8 mmole) and 10% palladium on carbon (0.25g) in methanol (50ml) and DMF (50ml) was shaken under an atmosphere of hydrogen at 50psi/344.8KPa for 18hours. The mixture was filtered and evaporated to dryness. The residue was partitioned between dichloromethane (75ml) and water (30ml). The organic phase was separated, washed with brine, dried (Na₂SO₄) and evaporated to dryness. Trituration of the residue with diethyl ether afforded the title compound as pale brown solid (1.15g).
- ¹H NMR (250MHz, CDCl₃) δ (ppm): 7.88 (s, 1H), 7.16 (d, 1H), 6.94 (d, 1H), 6.89 (d, 1H), 6.40 (dd, 1H), 3.49 (m, 2H), 2.95 (bd, 2H), 2.70 (m, 1H), 2.36 (s, 3H), 2.10 (m, 4H), 1.85 (m, 2H).

Description 3

4-(Pyridin-4-yl)naphth-1-ylamine (D3)

- A stirred suspension of 4-bromonaphth-1-ylamine (10g, 45 mmole) in 1,2-dimethoxyethane (400ml) and water (100ml) containing sodium carbonate (14g) was flushed with argon for 0.3 hours. Tetrakis(triphenylphosphine) palladium (0) (2.75g, 2.4 mmole) was added followed by pyridin-4-ylboronic acid (5.7g, 46 mmole) and the mixture heated at reflux for 5 hours. The mixture was concentrated *in vacuo* to a brown slurry and partitioned between dichloromethane and water. The aqueous was further extracted with dichloromethane and the combined organics dried (Na₂SO₄) and concentrated *in vacuo* to a brown solid (13.2g). Purification of the solid by flash chromatography eluting with ethyl acetate afforded the title compound as a yellow crystalline solid (7.8g, 78%).

¹H NMR (250MHz, CDCl₃) δ (ppm): 8.68 (d, 2H), 7.90 (d, 2H), 7.30 (m, 5H), 6.84 (d, 1H), 4.32 (s, 2H).

Description 4

1-Acetyl-7-(1-methyl-1,2,5,6-tetrahydropyridin-4-yl)-1,2,3,5-tetrahydropyrrolo[2,3-f]indole (D4)

- To a stirred suspension of 1-acetyl-1,2,3,5-tetrahydropyrrolo[2,3-f]indole (J. Med. Chem. 1995, 38, 2524) (1.60g, 8 mmole) and 1-methylpiperidin-4-one (1.81g, 16 mmole) in dry methanol (70ml) was added sodium methoxide (2.59g, 48 mmole). The mixture was heated at reflux under argon for 24 hours, then cooled and concentrated by evaporation to approx. 25% volume; then treated with water (5ml), stirred and the solid precipitate collected by filtration. The solid was suspended in ethanol (20ml), heated to boiling, cooled and filtered to leave the title compound as a pale cream powder (1.20g).
- ¹H NMR (250MHz, d⁶DMSO) δ (ppm): 11.03 (s, 1H), 8.61 (s, 1H), 7.32 (d, 1H), 7.23 (s, 1H), 6.03 (bs, 1H), 4.14 (t, 2H), 3.22 (t, 2H), 3.07 (d, 2H), 2.55 (m, 4H), 2.32 (s, 3H), 2.20 (s, 3H).

Description 5

- 1-Acetyl-7-(1-methylpiperidin-4-yl)-1,2,3,5-tetrahydropyrrolo[2,3-f]indole (D5)**
A mixture of 1-acetyl-7-(1-methyl-1,2,5,6-tetrahydropyridin-4-yl)-1,2,3,5-tetrahydropyrrolo[2,3-f]indole (D4, 1.10g, 3.7 mmole), 10% palladium on carbon (0.20g) in MeOH (50ml), DMF (10ml) and glacial acetic acid (0.5ml) was shaken under hydrogen at 50 psi/344.8kPa for 42 hours. The mixture was filtered through Celite (Diatomaceous Earth) and the filtrate evaporated to dryness. The residue was dissolved in water (10ml) and the pH adjusted to 8 with solid potassium carbonate. The precipitate was collected by filtration washed with water and dried *in vacuo* to leave the title compound as a buff powder (0.60g).
- ¹H NMR (250MHz, d⁶DMSO) δ (ppm): 10.79 (s, 1H), 8.42 (s, 1H), 7.32 (s, 1H), 7.15 (s, 1H), 4.25 (t, 2H), 3.34 (t, 2H), 3.04 (br d, 2H), 2.80 (m, 1H), 2.37 (s, 3H), 2.32 (s, 3H), 2.22-2.02 (m, 4H), 1.90 - 1.72 (m, 2H).

Description 6

- 7-(1-Methylpiperidin-4-yl)-1,2,3,5-tetrahydropyrrolo[2,3-f]indole (D6)**
To a stirred suspension of 1-acetyl-7-(1-methylpiperidin-4-yl)-1,2,3,5-tetrahydropyrrolo[2,3-f]indole (D5, 0.55g, 1.85 mmole) in ethanol (10ml) and 10% sodium hydroxide solution (10ml) was added sodium hydroxide pellets (0.50g) and the resultant mixture was heated at reflux under argon for 18 hours. The mixture was cooled, diluted with water (75ml) and extracted with dichloromethane (5x30 ml). The combined organic extracts were washed with brine, dried (MgSO₄) and evaporated to dryness. The

residue was triturated with diethyl ether and the solid filtered off and dried *in vacuo* to afford the title compound as an off-white powder (0.29g).

¹H NMR (250MHz, d⁶DMSO) δ(ppm): 10.16 (s, 1H), 7.06 (s, 1H), 6.74 (d, 1H), 6.50 (s, 1H), 4.89 (s, 1H), 3.32 (m, 2H), 2.87 - 2.74 (m, 4H), 2.51 (m, 1H), 2.12 (s, 3H), 1.96 - 1.76 (m, 4H), 1.64 - 1.49 (m, 2H).

Description 7

4-(Pyridin-4-yl)naphth-1-ylacetic acid (D7)

4-Bromonaphth-1-ylacetic acid (J. Org. Chem., 1951, 16, 1588) (1g, 3.78 mmole) in 1,2-dimethoxyethane (50ml) was treated with pyridin-4-ylboronic acid (465mg, 3.78 mmole), sodium hydrogen carbonate (952mg, 11.3 mmole) and water (10ml). A stream of argon was bubbled through the mixture for 15 minutes, then tetrakis(triphenylphosphine)palladium (0) (200mg 0.17 mmole) was added and the mixture heated under reflux for 18 hours. The mixture was then concentrated *in vacuo* to a gum, which was partitioned between 2M sodium hydroxide solution and dichloromethane. The aqueous layer was separated, adjusted to pH 0 with 6M hydrochloric acid and washed with dichloromethane; then adjusted to pH 7 by addition of aqueous potassium carbonate solution and extracted with dichloromethane. The dichloromethane extract was dried (Na₂SO₄) and concentrated *in vacuo* to give the title compound, which crystallised from ether as needles mp 210-215°C (465mg, 46%).
¹H NMR (250MHz, CDCl₃) δ (ppm): 8.55 (d, 2H), 8.0 (d, 1H), 7.7 (d, 1H), 7.5 - 7.3 (m, 5H), 7.2 (d, 1H), 6.1 (br s, 1H), 4.0 (s, 2H).

Description 8

25 N-[2,3-Dichloro-4-(pyridin-4-yl)phenyl]acetamide (D8)

The title compound was prepared from N-[4-bromo-2,3-dichlorophenyl]acetamide and pyridin-4-ylboronic acid using a similar procedure to Description 3.

¹H NMR (250MHz, d⁶DMSO) δ (ppm): 8.52 (d, 2H), 7.66 (d, 1H), 7.32 (d, 2H), 7.25 (d, 1H), 7.23 (br s, 1H), 1.98 (s, 3H).

Description 9

2,3-Dichloro-4-(pyridin-4-yl)aniline (D9)

A stirred suspension of N-[2,3-dichloro-4-(pyridin-4-yl)phenyl]acetamide (D8, 1g, 3.6 mmole) in a mixture of 2M NaOH solution and ethanol (30 ml) was heated under reflux for 36 hours. The mixture was concentrated *in vacuo* and the residue extracted with

dichloromethane. The extract was dried (Na_2SO_4) and concentrated *in vacuo* to afford the title compound as an orange solid (59%).

^1H NMR (250MHz, CDCl_3) δ (ppm): 8.64 (d, 2H), 7.32 (d, 2H), 7.05 (d, 1H), 6.85 (d, 1H), 4.40 (br s, 2H).

5

Description 10

N-[2-Chloro-4-(pyridin-4-yl)phenyl]acetamide (D10)

The title compound was prepared from N-[4-bromo-2-chlorophenyl]acetamide and pyridin-4-ylboronic acid using a similar procedure to Description 3.

10 ^1H NMR (250MHz, CDCl_3) δ (ppm): 8.65 (d, 2H), 7.72 (br s, 1H), 7.68 (d, 1H), 7.58 (dd, 1H), 7.48 (d, 2H), 2.29 (s, 3H). NH not discernible from spectrum.

Description 11

2-Chloro-4-(pyridin-4-yl)aniline (D11)

15 The title compound was prepared from N-[2-chloro-4-(pyridin-4-yl)phenyl]acetamide using a similar procedure to Description 9.

^1H NMR (250MHz, CDCl_3) δ (ppm): 8.60 (d, 2H), 7.60 (d, 1H), 7.43 (d, 2H), 7.40 (dd, 1H), 6.87 (d, 1H), 4.30 (br s, 2H).

20 Description 12

5-Nitro-3-(pyridin-4-yl)benzo[b]thiophene (D12)

A stirred mixture of 3-bromo-5-nitrobenzo[b]thiophene (J. Amer. Chem. Soc, 1948, 1955) (4.2g, 0.016 mole,) pyridin-4-ylboronic acid (2.0g, 0.016 mole) and sodium carbonate (4.3g, 0.048 mole) in DME (150 ml) and water (150 ml) was de-gassed by bubbling argon through for 15 minutes, then tetrakis(triphenylphosphine)palladium (0) (400 mg) was added and the mixture heated at reflux under argon for 18 hours. The reaction mixture was cooled and concentrated *in vacuo* to approx 150 ml volume, then acidified with 2M HCl acid (200 ml) and shaken well with ethyl acetate (400 ml). The solid present was filtered off, shaken with 10% Na_2CO_3 solution and dichloromethane, and the organic layer separated, dried (Na_2SO_4) and concentrated *in vacuo* to afford the title compound as an orange/yellow solid (2.3g, 56%).

25

30

^1H NMR (250 MHz, CDCl_3) δ (ppm): 8.82-8.77 (m, 2H), 8.29 (dd, 1H), 8.07 (d, 1H), 7.77 (s, 1H), 7.52 (dd, 1H).

35

Description 13

3-(1-Methyl-1,2,5,6-tetrahydropyridin-4-yl)-5-nitrobenzo[b]thiophene (D13)

- A solution of 5-nitro-3-(pyridin-4-yl)benzo[b]thiophene (D12, 1.5g, 5.9 mmole) in chloroform (100ml) was treated with iodomethane (0.55 ml, 8.8 mmole) and kept at room temperature for 11 days. The solid was filtered off, washed with chloroform and dried to afford the quaternary salt (2.11g, 90%). This material was dissolved in a mixture of water (50 ml) and ethanol (50 ml) and treated portionwise over 10 minutes with sodium borohydride (0.50g, 0.013 mole) at room temperature under argon. The reaction mixture was stirred for a further 2 hours, then concentrated under vacuum. The residue was treated with 10% Na₂CO₃ solution (50 ml) and extracted with dichloromethane. The extract was dried (Na₂SO₄), concentrated *in vacuo* and the residue purified by chromatography on basic alumina eluting with ethyl acetate to afford the title compound as a yellow solid (1.2g, 83%).
- ¹H NMR (250 MHz, CDCl₃) δ (ppm) : 8.82 (d, 1H), 8.19 (dd, 1H), 7.94 (d, 1H), 6.09 (quintet, 1H), 3.24-3.19 (m, 2H), 2.77-2.72 (m, 2H), 2.66-2.62 (m, 2H), 2.46 (s, 3H).

15 Description 14

- 5-Amino-3-(1-methyl-1,2,5,6-tetrahydropyridin-4-yl)benzo[b]thiophene (D14)**
A stirred solution of 3-(1-methyl-1,2,5,6-tetrahydropyridin-4-yl)-5-nitrobenzo[b]thiophene (D13, 470mg, 1.7 mmole) in ethanol (35ml) at 60°C under argon was treated over 5 minutes with a solution of tin (II) chloride (2.0g, 10.5 mmole) in concentrated HCl acid (4 ml) and the mixture then heated at reflux for 1.5 hours. The reaction mixture was allowed to cool and the precipitate filtered off, washed with ethanol and dried. This was then shaken well with 10% Na₂CO₃ solution (50ml) and dichloromethane (100ml), and the organic layer separated, dried (Na₂SO₄) and concentrated *in vacuo* to afford the title compound as a yellow oil (310mg, 75%).
- ¹H NMR (HCl salt) (250 MHz d⁶ DMSO) δ (ppm) : 10.7 (s, 1H) 8.08 (d, 1H), 7.99 (d, 1H), 7.33 (dd, 1H), 6.04 (brs, 1H), 4.05-3.70 (m, 4H), 3.70-3.50 (m, 2H), 3.40-3.20 (m, 2H), 2.85 (s, 3H).

Description 15

- 5-Amino-3-(1-methylpiperidin-4-yl)benzo[b]thiophene (D15)**
The title compound was prepared from 3-(1-methyl-1,2,5,6-tetrahydropyridin-4-yl)-5-nitrobenzo[b]thiophene (D13) using a similar procedure to Description 2 as a pink solid (72%).
- ¹H NMR (250 MHz, CDCl₃) δ (ppm) : 7.61 (d, 1H), 7.06 (d + s, 2H), 6.78 (dd, 1H), 3.73 (br s, 2H), 3.05-2.95 (br d, 2H), 2.80 (tt, 1H), 2.35 (s, 3H), 2.20-2.02 (m, 2H), 1.96-1.74 (m, 4H).

Example 1

N-[3-(1-Methylpiperidin-4-yl)indol-5-yl]-N'-[4-(pyridin-4-yl)naphth-1-yl]-urea (E1)

- 5 To a stirred solution of triphosgene (0.09g, 0.31 mmole) in dichloromethane (15ml) under argon, was added dropwise a solution of 4-(pyridin-4-yl)naphth-1-ylamine (D3, 0.17g, 0.77 mmole) and triethylamine (0.12ml, 0.83 mmole) in dichloromethane (10ml). The mixture was then stirred at room temperature for 20 minutes, then a solution of 5-amino-3-(1-methylpiperidin-4-yl)-1H-indole (D2, 0.15g, 0.66 mmole) in dichloromethane
- 10 (10ml) was slowly added. After stirring the mixture for 1 hour, dilute potassium carbonate solution (10ml) was added. The precipitated solid mass was collected and purified by flash chromatography on silica gel eluting with CH₂Cl₂/MeOH/NH₄OH (100:10:1) to afford the title compound as a buff powder (0.14g).
- ¹H NMR (250MHz, d⁶DMSO) δ (ppm): 10.72 (s, 1H), 9.02 (s, 1H), 8.87 (s, 1H), 8.72 (d, 2H), 8.29 (d, 1H), 8.24 (d, 1H), 7.86 (m, 2H), 7.71 - 7.48 (m, 5H), 7.32 (d, 1H), 7.14 (d, 1H), 7.08 (s, 1H), 2.95 (d, 2H), 2.72 (m, 1H), 2.27 (s, 3H), 2.18 (m, 2H), 1.96 (m, 2H), 1.78 (m, 2H).
- 15

Example 2

- 20 **N-[3-(1-Methylpiperidin-4-yl)indol-5-yl]-N'-[3-methyl-4-(pyridin-4-yl)phenyl]-urea (E2)**

- The title compound was prepared in a similar manner to Example 1 from 3-methyl-4-(pyridin-4-yl)aniline (prepared as for D3 from 4-bromo-3-methylaniline) (0.17g, 0.9 mmole), 5-amino-3-(1-methylpiperidin-4-yl)-1H-indole (D2, 0.17g, 0.75 mmole),
- 25 triphosgene (0.10g, 0.35 mmole) and triethylamine (0.07ml). This was obtained as a buff powder (0.11g).
- ¹H NMR (250MHz, d⁶DMSO) δ (ppm): 10.64 (s, 1H), 8.62 (s, 1H), 8.57 (d, 2H), 8.47 (s, 1H), 7.73 (s, 1H), 7.37 (m, 4H), 7.24 - 6.98 (m, 4H), 2.87 (m, 2H), 2.63 (m, 1H), 2.26 (s, 3H), 2.19 (s, 3H), 2.05 - 1.85 (m, 4H), 1.70 (m, 2H).
- 30

Example 3

N-[2,3-Dichloro-4-(pyridin-4-yl)phenyl]-N'-[3-(1-methylpiperidin-4-yl)indol-5-yl]-urea (E3)

- The title compound was prepared in a similar manner to Example 1 from 2,3-dichloro-4-(pyridin-4-yl)aniline (D9, 0.20g, 0.85 mmole), 5-amino-3-(1-methylpiperidin-4-yl)-1H-
- 35

indole (D2, 0.15g, 0.66 mmole), triphosgene (0.10g, 0.34 mmole) and triethylamine (0.30ml). This was obtained as a pink white solid (0.18g).

¹H NMR (250MHz, d⁶DMSO) δ (ppm): 10.68 (s, 1H), 9.39 (s, 1H), 8.50 (d, 2H), 8.45 (s, 1H), 8.20 (d, 1H), 7.68 (s, 1H), 7.31 (d, 2H), 7.25 (d, 1H), 7.12 (d, 1H), 6.96 (s, 1H), 6.83 (d, 1H), 3.30 (m, 1H), 2.97 (m, 2H), 2.72 (s, 3H), 1.98 - 1.78 (m, 6H).

Example 4

N-[2-Chloro-4-(pyridin-4-yl)phenyl]-N'-[3-(1-methylpiperidin-4-yl)indol-5-yl]-urea (E4)

The title compound was prepared in a similar manner to Example 1 from 2-chloro-4-(pyridin-4-yl)aniline (D11, 0.18g, 0.88 mmole), 5-amino-3-(1-methylpiperidin-4-yl)-1H-indole (D2, 0.15g, 0.66 mmole), triphosgene (0.10g, 0.34 mmole) and triethylamine (0.3ml). This was obtained as a pink-white solid (0.20g).

¹H NMR (250MHz, d⁶DMSO) δ (ppm): 10.66 (s, 1H), 9.34 (s, 1H), 8.40 (d, 2H), 8.32 (s, 1H), 8.22 (d, 1H), 7.76 (d, 1H), 7.64 - 7.53 (m, 4H), 7.12 (d, 1H), 6.93 (s, 1H), 6.82 (d, 1H), 3.24 (m, 1H), 2.94 (m, 2H), 2.57 (s, 3H), 1.97-1.77 (m, 6H).

Example 5

N-[3-(1-Methylpiperidin-4-yl)indol-5-yl]-4-(pyridin-4-yl)naphth-1-ylacetamide (E5)

A stirred suspension of 4-(pyridin-4-yl)naphth-1-ylacetic acid (D7, 0.18g, 0.7 mmole) in dichloromethane (15ml) was treated with oxalyl chloride (0.18ml, 2.1 mmole), then stirred at room temperature for 3 hours, before evaporating to dryness. The solid residue was suspended in dichloromethane (15ml), cooled to 0°C and treated with a solution of 5-amino-3-(1-methylpiperidin-4-yl)-1H-indole (D2, 0.13g, 0.56 mmole) in dichloromethane (15ml). The mixture was stirred at 0° for 1 hour and then a solution of triethylamine (0.25ml) in dichloromethane (5ml) was added dropwise. The mixture was allowed to warm to room temperature and stir overnight, then evaporated to dryness and the residue subjected to flash chromatography on silica gel eluting with CH₂Cl₂/MeOH/NH₄OH (100:5:0.5 to 100:10:1 gradient elution) to afford the title compound as a pale cream powder (0.04g).

¹H NMR (250MHz, CDCl₃) δ (ppm): 8.75 (d, 2H), 8.20 (d, 1H), 8.05 (s, 1H), 7.91 (d, 1H), 7.76 (s, 1H), 7.62 - 7.43 (m, 6H), 7.22 (m, 2H), 6.97 (m, 2H), 4.26 (s, 2H), 2.97 (d, 2H), 2.73 (m, 1H), 2.32 (s, 3H), 2.13 - 1.95 (m, 4H), 1.77 (m, 2H).

Example 6

N-[2,3-Dichlorophenyl]-N'-[7-(1-methylpiperidin-4-yl)-1,2,3,5-tetrahydropyrrolo[2,3-f]indol-1-yl]-urea (E6)

- To a stirred solution of 7-(1-methylpiperidin-4-yl)-1,2,3,5-tetrahydropyrrolo[2,3-f]indole (D6, 0.10g, 0.4 mmole) in dichloromethane (10ml) was added dropwise a solution of 2,3-dichlorophenylisocyanate (0.08g, 0.44 mmole) in dichloromethane (10ml). The mixture was stirred at room temperature overnight, then concentrated by evaporation and diethyl ether (10ml) added. The precipitated solid was collected by filtration, washed with diethyl ether and dried *in vacuo* to afford the title compound as a colourless powder (0.12g).
- ¹H NMR (250MHz, d⁶DMSO) δ(ppm): 10.49 (s, 1H), 8.21 (s, 1H), 7.92 (s, 1H), 7.64 (d, 1H), 7.40 - 7.25 (m, 2H), 7.08 (s, 1H), 6.88 (d, 1H), 4.08 (t, 2H), 3.15 (t, 2H), 2.78 (d, 2H), 2.50 (m, 1H), 2.10 (s, 3H), 1.95-1.75 (m, 4H), 1.65-1.57 (m, 2H).

Example 7

- N-[7-(1-Methylpiperidin-4-yl)-1,2,3,5-tetrahydropyrrolo[2,3-f]indol-1-yl]-N'-[4-(pyridin-4-yl)naphth-1-yl]-urea (E7)**

- The title compound was prepared in a similar manner to Example 1 from 4-(pyridin-4-yl)naphth-1-ylamine (D3, 0.16g, 0.7 mmole), 7-(1-methylpiperidin-4-yl)-1,2,3,5-tetrahydropyrrolo[2,3-f]indole (D6, 0.15g, 0.6 mmole), triphosgene (0.08g, 0.28 mmole) and triethylamine (0.25ml). This was obtained as a cream powder (0.11g).
- ¹H NMR (250MHz, d⁶DMSO) δ(ppm): 10.64 (s, 1H), 8.90 (dd, 3H), 8.35 (dd, 1H), 8.20 (s, 1H), 7.95 (dd, 1H), 7.83 (d, 1H), 7.80 - 7.62 (m, 5H), 7.34 (s, 1H), 7.12 (d, 1H), 4.50 (t, 2H), 3.45 (t, 2H), 2.95 (d, 2H), 2.77 (m, 1H), 2.32 (s, 3H), 2.17 - 2.04 (m, 4H), 1.88 - 1.76 (m, 2H).

Example 8

N-[3-Chloro-4-(pyridin-4-yl)phenyl]-N'-[3-(1-methylpiperidin-4-yl)indol-5-yl]-urea (E8)

- The title compound was prepared in a similar manner to Example 1 from 3-chloro-4-(pyridin-4-yl)aniline (prepared using a similar procedure to Description 11) (0.18g, 0.88 mmole), 5-amino-3-(1-methylpiperidin-4-yl)-1H-indole (D2, 0.15g, 0.66 mmole), triphosgene (0.10g, 0.34 mmole) and triethylamine (0.3ml). This was obtained as a off-white powder.
- ¹H NMR (250MHz, d⁶DMSO) δ(ppm): 10.54 (s, 1H), 8.92 (s, 1H), 8.54 (s, 1H), 8.49 (d, 2H), 7.75 (s, 1H), 7.60 (s, 1H), 7.34 (d, 2H), 7.28 (m, 2H), 7.09 (d, 1H), 6.91 (m, 2H), 2.76 (d, 2H), 2.52 (m, 1H), 2.08 (s, 3H)

Example 9

N-[3-Chloro-4-(pyridin-4-yl)phenyl]-N'-[3-(1-methyl-1,2,5,6-tetrahydropyridin-4-yl)benzo[b]thiophen-5-yl]-urea (E9)

- 5 The title compound was prepared from 3-chloro-4-(pyridin-4-yl)aniline (prepared using a similar procedure to Description 11) and 5-amino-3-(1-methyl-1,2,5,6-tetrahydropyridin-4-yl)benzo[b]thiophene (D14) using a similar procedure to Example 1 as a beige solid (41%).

¹H NMR (250 MHz, CDCl₃) δ (ppm) : 8.57 (d, 2H), 8.36 (s, 1H), 8.18 (s, 1H), 7.98 (s, 1H), 7.56 (d, 1H), 7.42 (s, 1H), 7.30-7.12 (m, 3 H), 7.09 (d, 1H), 7.00 (d, 1H), 5.90 (br s, 1H), 3.02 (br s, 2H), 2.65-2.45 (m, 4H), 2.34 (s, 3H).

Example 10

N-[3-(1-Methyl-1,2,5,6-tetrahydropyridin-4-yl)benzo[b]thiophen-5-yl]-N'-[4-(pyridin-4-yl)naphth-1-yl]-urea (E10)

- 15 The title compound was prepared from 4-(pyridin-4-yl)naphth-1-ylamine (D3) and 5-amino-3-(1-methyl-1,2,5,6-tetrahydropyridin-4-yl)benzo[b]thiophene (D14) using a similar procedure to Example 1 as a beige solid (48%).

¹H NMR (250 MHz, CDCl₃) δ (ppm) : 8.69-8.64 (m, 2H), 8.00-7.95 (m, 2H), 7.80-7.72 (m, 4H), 7.55 (d, 1H), 7.44-7.17 (m, 7H), 5.91 (br s, 1H), 3.03-2.96 (m, 2H), 2.65-2.48 (m, 4H), 2.32 (s, 3H)

Example 11

N-[3-Chloro-4-(pyridin-4-yl)phenyl]-N'-[3-(1-methylpiperidin-4-yl)benzo[b]thiophen-5-yl]-urea (E11)

- 25 The title compound was prepared from 3-chloro-4-(pyridin-4-yl)aniline (D11) and 5-amino-3-(1-methylpiperidin-4-yl)benzo[b]thiophene (D15) using a similar procedure to Example 1 as a white solid (41%).

¹H NMR (250 MHz, CDCl₃) δ (ppm) : 8.60-8.55 (m, 2H), 8.25 (brs, 1H), 8.20 (brs, 1H), 8.00 (d, 1H), 7.75 (d, 1H), 7.70 (d, 1H), 7.47 (dd, 1H), 7.42-7.33 (m, 3H), 7.23 (d, 1H), 7.17 (s, 1H), 3.07-2.80 (m, 3H), 2.36 (s, 3H), 2.29-2.15 (m, 2H), 2.04-1.90 (m, 4H).

Example 12

N-[3-(1-Methylpiperidin-4-yl)benzo[b]thiophen-5-yl]-N'-[4-(pyridin-4-yl)naphth-1-yl]-urea (E12)

- 35

The title compound was prepared from 4-(pyridin-4-yl)naphth-1-ylamine (D3) and 5-amino-3-(1-methylpiperidin-4-yl)benzo[b]thiophene (D15) using a similar procedure to Example 1 (E1) as a white solid (43%).

- 5 ^1H NMR (250 MHz, CDCl_3) δ (ppm) : 8.73-8.67 (m, 2H), 8.05-7.97 (m, 2H), 7.86-7.77 (m, 2H), 7.66 (d, 1H), 7.50-7.28 (m, 7H), 7.14-7.05 (m, 2H), 3.00-2.75 (m, 3H), 2.28 (s, 3H), 2.10-1.80 (m, 6H).

Pharmacological Data


- 10 The affinities of the compounds of this invention were determined by methods described above.

5-HT_{1A}, 5-HT_{1B} and 5-HT_{1D} Receptor Binding

- 15 Examples 1, 3, 4, 8, 9, 10 and 12 had pKi values >8.0 at 5-HT_{1A}, 5-HT_{1B} and 5-HT_{1D} receptors.

CLAIMS


1. A compound of formula (I) or a salt thereof:



5

(I)

in which R^a is a group of formula (i)



(i)

10 in which P^1 is phenyl, bicyclic aryl, a 5 to 7 membered heterocyclic ring containing 1 to 3 heteroatoms selected from oxygen, nitrogen and sulphur, or a bicyclic heterocyclic ring containing 1 to 3 heteroatoms selected from oxygen, nitrogen and sulphur;

R^1 is hydrogen, halogen, C_{1-6} alkyl, C_{3-6} cycloalkyl, COC_{1-6} alkyl, C_{1-6} alkoxy, hydroxy, hydroxy C_{1-6} alkyl, hydroxy C_{1-6} alkoxy, C_{1-6} alkoxy C_{1-6} alkoxy, nitro, trifluoromethyl, cyano, SR^9 , SOR^9 , SO_2R^9 , $SO_2NR^{10}R^{11}$, CO_2R^{10} , $CONR^{10}R^{11}$, $CONR^{10}(CH_2)_cCO_2R^{11}$, $(CH_2)_cNR^{10}R^{11}$, $(CH_2)_cCONR^{10}R^{11}$, $(CH_2)_cNR^{10}COR^{11}$, $(CH_2)_cCO_2C_{1-6}$ alkyl, $CO_2(CH_2)_cOR^{10}$, $NR^{10}R^{11}$, $NR^{10}CO_2R^{11}$, $NR^{10}CONR^{10}R^{11}$, $CR^{10}=NOR^{11}$ where R^9 is C_{1-6} alkyl, R^{10} and R^{11} are independently hydrogen or C_{1-6} alkyl and c is 1 to 4;

20 R^2 is hydrogen, halogen, C_{1-6} alkyl, C_{3-6} cycloalkyl, C_{3-6} cycloalkenyl, C_{1-6} alkoxy, COC_{1-6} alkyl, aryl, acyloxy, hydroxy, nitro, trifluoromethyl, cyano, CO_2R^{10} , $CONR^{10}R^{11}$, $NR^{10}R^{11}$ where R^{10} and R^{11} are as defined for R^1 ;

a is 1, 2 or 3;

or R^a is a group of formula (ii)

25



(ii)

wherein P^2 and P^3 are independently phenyl, bicyclic aryl, a 5- to 7- membered heterocyclic ring containing 1 to 3 heteroatoms selected from oxygen, nitrogen and

sulphur, or a bicyclic heterocyclic group containing 1 to 3 heteroatoms selected from oxygen, nitrogen or sulphur;

A is a bond or oxygen, $S(O)_m$ where m is 0, 1 or 2, carbonyl, or CH_2 or NR^4 where R^4 is hydrogen or C_{1-6} alkyl;

- 5 R^1 is as defined above for formula (i) or is a 5 to 7-membered heterocyclic ring, containing 1 to 3 heteroatoms selected from oxygen, nitrogen or sulphur, optionally substituted by C_{1-6} alkyl, halogen or C_{1-6} alkanoyl;
 R^2 and R^3 are as defined for R^2 in formula (i);
 and a and b are independently 1, 2 or 3;

10

L is a group of formula

- Y - C (=V) - DG -

in which Y is - NH -, NR^5 where R^5 is C_{1-6} alkyl, or Y is - CH_2 - or - O -;

V is oxygen or sulphur;

- 15 D is nitrogen, carbon or a CH group, G is hydrogen or C_{1-6} alkyl, providing that D is nitrogen or a CH group, or G together with R^b forms a group W where W is $(CR^{16}R^{17})_t$ where t is 2, 3 or 4 and R^{16} and R^{17} are independently hydrogen or C_{1-6} alkyl or W is $(CR^{16}R^{17})_{u-J}$ where u is 0, 1, 2 or 3 and J is oxygen, sulphur, $CR^{16}=CR^{17}$, $CR^{16}=N$, $=CR^{16}O$, $=CR^{16}S$ or $=CR^{16}.NR^{17}$ provided that u is not 0 when J is oxygen or sulphur;

20

subject to the proviso that when D is nitrogen, G is hydrogen or C_{1-6} alkyl, Q is selected such that together with the phenyl ring to which it is attached it forms an indole ring and further that when:

- (a) Y is -NH- or $-NR^{5-}$ and V is oxygen or sulphur; or
 25 (b) both Y and V are oxygen; or
 (c) Y is CH_2 and V is oxygen
 then P^1 is not phenyl within the definition of R^a formula (i) and
 R^a is not an unsubstituted biphenyl within the definition of formula (ii)


- 30 Q is an optionally substituted 5- to 7- membered carbocyclic or heterocyclic ring containing 1 to 3 heteroatoms selected from oxygen, nitrogen or sulphur;
 RY is a 5- to 7-membered heterocyclic ring containing 1 to 3 heteroatoms selected from oxygen, nitrogen and sulphur;
 R^b is hydrogen, halogen, hydroxy, C_{1-6} alkyl, trifluoromethyl, C_{1-6} alkoxy or aryl; or R^b
 35 together with G forms a group W as defined above;

2. A compound according to claim 1 in which R² and/or R³ are each hydrogen, halogen or a C₁₋₆ alkyl group.
- 5 3. A compound according to any of the preceding claims in which Y is -NH-
4. A compound according to any of the preceding claims in which D is nitrogen and G is a hydrogen atom.
- 10 5. A compound according to any of the preceding claims in which Q is a 5- or 6-membered ring containing 1 or 2 heteroatoms.
6. A compound according to claim 1 which is:
- 15 N-[3-(1-Methylpiperidin-4-yl)indol-5-yl]-N'-[4-(pyridin-4-yl)naphth-1-yl]-urea,
N-[3-(1-Methylpiperidin-4-yl)indol-5-yl]-N'-[3-methyl-4-(pyridin-4-yl)phenyl]-urea,
N-[2,3-Dichloro-4-(pyridin-4-yl)phenyl]-N'-[3-(1-methylpiperidin-4-yl)indol-5-yl]-urea,
N-[2-Chloro-4-(pyridin-4-yl)phenyl]-N'-[3-(1-methylpiperidin-4-yl)indol-5-yl]-urea,
N-[3-(1-Methylpiperidin-4-yl)indol-5-yl]-4-(pyridin-4-yl)naphth-1-ylacetamide,
N-[2,3-Dichlorophenyl]-N'-[7-(1-methylpiperidin-4-yl)-1,2,3,5-tetrahydropyrrolo[2,3-
20 f]indol-1-yl]-urea,
N-[7-(1-Methylpiperidin-4-yl)-1,2,3,5-tetrahydropyrrolo[2,3-f]indol-1-yl]-N'-[4-(pyridin-4-yl)naphth-1-yl]-urea,
N-[3-Chloro-4-(pyridin-4-yl)phenyl]-N'-[3-(1-methylpiperidin-4-yl)indol-5-yl]-urea,
N-[3-Chloro-4-(pyridin-4-yl)phenyl]-N'-[3-(1-methyl-1,2,5,6-tetrahydropyridin-4-
25 yl)benzo[b]thiophen-5-yl]-urea,
N-[3-(1-Methyl-1,2,5,6-tetrahydropyridin-4-yl)benzo[b]thiophen-5-yl]-N'-[4-(pyridin-4-yl)naphth-1-yl]-urea,
N-[3-Chloro-4-(pyridin-4-yl)phenyl]-N'-[3-(1-methylpiperidin-4-yl)benzo[b]thiophen-5-yl]-urea,
30 N-[3-(1-Methylpiperidin-4-yl)benzo[b]thiophen-5-yl]-N'-[4-(pyridin-4-yl)naphth-1-yl]-urea
or a pharmaceutically acceptable salt thereof.
7. A process for the preparation of a compound of formula (I) or a
35 pharmaceutically acceptable salt thereof according to claim 1 which comprises:
(a) where D is nitrogen and Y is NH, coupling a compound of formula (II):



(II)


in which R^a and V are as defined in formula (I) or a protected derivative thereof with a
 5 compound of formula (III).



(III)

in which R^b , R^y , G, and Q are as defined in formula (I), or a protected derivative thereof;
 10 or


(b) where D is nitrogen and Y is NH or NR^5 , reacting a compound of formula (IV)



(IV)

15 in which R^a and R^5 are as defined in formula (I) with a compound of formula (III)
 together with an appropriate urea forming agent;

(c) where D is nitrogen, reacting a compound of formula (V)



(V)

20 in which R^a is as defined in formula (I),


Y is $-CH_2-$ or $-O-$ and L^2 is an appropriate leaving group, with a compound of formula
 (III);

(d) where D is carbon or CH, reacting a compound of formula (VI)



(VI)

25 in which R^a is as defined in formula (I) with a compound of formula (VII)



(VII)

in which D is carbon or CH, R^b, RY, G, and Q are as defined in formula (I) and L² is an appropriate leaving group and optionally thereafter:

- removing any protecting groups,
- 5 • converting a compound of formula (I) into another compound of formula (I),
- forming a pharmaceutically acceptable salt.

8. A compound according to any of claims 1 to 6 for use in therapy.

- 10 9. A pharmaceutical composition which comprises a compound according to any of claims 1 to 6 and a pharmaceutically acceptable carrier.

10. Use of a compound according to any one of the claims 1 to 6 for the manufacture of a medicament for the treatment of anxiety and/or depression.

INTERNATIONAL SEARCH REPORT

In national Application No.

PCT/EP 98/05116

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C07D401/14 A61K31/44 C07D487/04 C07D409/14

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C07D A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP 0 733 628 A (LILLY CO ELI) 25 September 1996 cited in the application see claim 1 ---	1-10
X	WO 94 24127 A (PFIZER LTD ;PFIZER (US); PFIZER RES & DEV (IE); WYTHES MARTIN JAME) 27 October 1994 see claim 1 ---	1-10
Y	WO 95 28400 A (GLAXO GROUP LTD ;NORTH PETER CHARLES (GB); WADMAN SJOERD NICOLAAS) 26 October 1995 see claim 1 ---	1-10
Y	WO 95 06636 A (PFIZER ;MACOR JOHN E (US)) 9 March 1995 see claim 1 ---	1-10
	--- -/-	



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"I" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance, the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance, the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"S" document member of the same patent family

Date of the actual completion of the international search

16 December 1998

Date of mailing of the international search report

13/01/1999

Name and mailing address of the ISA
European Patent Office, P.B. 5818 Patentplan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Gettins, M

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/EP 98/05116

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 95 06044 A (SMITHKLINE BEECHAM PLC ;DUCKWORTH DAVID MALCOLM (GB); GASTER LARAM) 2 March 1995 see claim 1 ---	1-10
Y	EP 0 581 538 A (MERCK SHARP & DOHME) 2 February 1994 see claim 1 ---	1-10
Y	WO 93 11106 A (PFIZER) 10 June 1993 see claim 1 ---	1-10
P,A	EP 0 812 826 A (LILLY CO ELI) 17 December 1997 see claim 1 ---	1-10
A	WO 95 32196 A (MERCK SHARP & DOHME ;CASTRO PINEIRO JOSE LUIS (GB); CHAMBERS MARK) 30 November 1995 see claim 1 ---	1-10
A	GB 2 289 465 A (MERCK SHARP & DOHME) 22 November 1995 see claim 1 ---	1-10
A	EP 0 533 268 A (GLAXO GROUP LTD) 24 March 1993 cited in the application see claim 1 ---	1-10
A	EP 0 533 267 A (GLAXO GROUP LTD) 24 March 1993 cited in the application see claim 1 ---	1-10
A	EP 0 533 266 A (GLAXO GROUP LTD) 24 March 1993 cited in the application see claim 1 -----	1-10

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No.

PCT/EP 98/05116

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 0733628 A	25-09-1996	AU 5311296 A	08-10-1996
		BR 9601061 A	06-01-1998
		CA 2215322 A	26-09-1996
		CN 1184425 A	10-06-1998
		CZ 9702888 A	18-02-1998
		NO 974220 A	04-11-1997
		PL 322843 A	16-02-1998
		WO 9629075 A	26-09-1996
		US 5708008 A	13-01-1998
WO 9424127 A	27-10-1994	AT 144773 T	15-11-1996
		AU 6567094 A	08-11-1994
		BR 9406481 A	09-01-1996
		CN 1121348 A	24-04-1996
		CZ 9502745 A	13-03-1996
		DE 69400824 D	05-12-1996
		DE 69400824 T	13-03-1997
		DK 695301 T	09-12-1996
		EP 0695301 A	07-02-1996
		ES 2094653 T	16-01-1997
		FI 954944 A	17-10-1995
		GR 3021804 T	28-02-1997
		HU 73807 A	30-09-1996
		JP 2802169 B	24-09-1998
		JP 8507083 T	30-07-1996
		NO 954168 A	19-10-1995
		NZ 265269 A	25-09-1996
		PL 311204 A	05-02-1996
		US 5607960 A	04-03-1997
		ZA 9402722 A	20-10-1995
WO 9528400 A	26-10-1995	AU 2343995 A	10-11-1995
WO 9506636 A	09-03-1995	AT 170836 T	15-09-1998
		AU 686654 B	12-02-1998
		AU 6979694 A	22-03-1995
		BR 9407402 A	05-11-1996
		CA 2169179 A	09-03-1995
		CN 1129933 A	28-08-1996
		CZ 9600599 A	12-06-1996
		DE 69413240 D	15-10-1998
		EP 0716649 A	19-06-1996
		FI 943976 A	01-03-1995
		HU 75646 A	28-05-1997
		JP 8511032 T	19-11-1996
		NO 960818 A	28-02-1996
		NZ 267487 A	22-09-1997
		PL 313227 A	10-06-1996
		ZA 9406608 A	28-02-1996
WO 9506044 A	02-03-1995	DE 69411176 D	23-07-1998
		DE 69411176 T	12-11-1998
		EP 0714389 A	05-06-1996
		JP 9504004 T	22-04-1997
EP 0581538 A	02-02-1994	AU 4215593 A	03-02-1994
		CA 2101219 A	31-01-1994
		CN 1089262 A,B	13-07-1994

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No.

PCT/EP 98/05116

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
EP 0581538	A		WO 9403446 A IL 106445 A JP 2599557 B JP 6184139 A MX 9304595 A US 5554629 A ZA 9305429 A	17-02-1994 04-01-1998 09-04-1997 05-07-1994 28-02-1994 10-09-1996 14-04-1994
WO 9311106	A	10-06-1993	AU 671959 B AU 2896192 A BR 9206810 A CA 2124206 A CN 1072679 A CZ 9401280 A EP 0619805 A FI 942395 A HU 69705 A JP 8239363 A JP 6510793 T MX 9206762 A NO 941918 A NZ 245243 A NZ 272130 A PL 173875 B PT 101087 A US 5639752 A ZA 9209082 A	19-09-1996 28-06-1993 31-10-1995 10-06-1993 02-06-1993 15-02-1995 19-10-1994 24-05-1994 28-09-1995 17-09-1996 01-12-1994 01-05-1993 24-05-1994 21-12-1995 24-06-1997 29-05-1998 30-06-1994 17-06-1997 24-05-1994
EP 0812826	A	17-12-1997	AU 3390797 A WO 9747302 A	07-01-1998 18-12-1997
WO 9532196	A	30-11-1995	AU 694226 B AU 2529695 A CA 2190501 A EP 0759918 A JP 10501212 T US 5807857 A	16-07-1998 18-12-1995 30-11-1995 05-03-1997 03-02-1998 15-09-1998
GB 2289465	A	22-11-1995	US 5552402 A	03-09-1996
EP 0533268	A	24-03-1993	AP 303 A AU 656021 B AU 2453092 A CA 2078505 A CN 1071919 A FI 924160 A HU 65608 A IL 103198 A JP 6116251 A MX 9205280 A NZ 244373 A RU 2077535 C US 5510350 A US 5340810 A ZA 9207108 A CN 1076195 A	28-01-1994 19-01-1995 25-03-1993 19-03-1993 12-05-1993 19-03-1993 28-07-1994 18-06-1996 26-04-1994 01-03-1993 28-03-1995 20-04-1997 23-04-1996 23-08-1994 08-09-1993 15-09-1993
EP 0533267	A	24-03-1993	AU 2452892 A	25-03-1993

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No.

PCT/EP 98/05116

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 0533267 A		AU 2568792 A	27-04-1993
		CA 2078507 A	19-03-1993
		CN 1073430 A	23-06-1993
		CZ 9400611 A	16-11-1994
		WO 9306084 A	01-04-1993
		FI 941261 A	17-03-1994
		JP 6107637 A	19-04-1994
		MX 9205278 A	01-03-1993
		NO 940974 A	17-03-1994
		US 5358948 A	25-10-1994
		ZA 9207106 A	17-03-1994
EP 0533266 A	24-03-1993	AU 2452992 A	25-03-1993
		CA 2078506 A	19-03-1993
		CN 1071922 A	12-05-1993
		FI 924159 A	19-03-1993
		HU 66319 A	28-11-1994
		JP 6107649 A	19-04-1994
		MX 9205279 A	01-03-1993
		US 5356893 A	18-10-1994
		ZA 9207107 A	08-09-1993